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Despite a diverse armamentarium of active drugs and response
rates that now exceed 70%, the survival impact of chemotherapy
in metastatic breast cancer is limited, and the disease remains
essentially incurable (Cold et al, 1992). This frustrating, partial
chemosensitivity prompted investigators to explore potential clin-
ical applications of the relationship that had been demonstrated in
laboratory models between drug dose and anti-cancer effect
(Teicher et al, 1988). Random assignment trials, in which varia-
tions in dose within the 'standard' range (i.e. doses that could be
administered without specialized haematopoietic support) were
studied, yielded modest and inconsistent results; however the
degree of dose escalation that had been attempted in these trials
was relatively minor in comparison with that achieved in the labo-
ratory (Hortobagyi et al, 1987; Bastholt et al, 1996).
The development ofmarrow autografting facilitated the study of
very high doses of some drugs, prominently the alkylating agents,
and allowed clinical investigators to mimic the levels of drug
exposure that had been assayed in the preclinical systems. The first
trials of high-dose chemotherapy with autograft support in breast
cancer were performed in patients with disease that had failed
conventional treatment. While high rates of response were
achieved, indicating that dose escalation could indeed partly over-
come drug resistance, these responses were of brief duration. In
addition treatment-related mortality occurred in up to 20% of
patients (Eder et al, 1986). In subsequent studies in patients
without prior chemotherapy for metastases, approximately 50%
achieved remission and, provocatively, a minority of these
remained durable (Peters et al, 1988; Ghallie et al, 1994).
Investigators next turned to a strategy based on an interpretation
ofthe work ofNorton and Simon (1986). According to their kinetic
model, cancer cells grew and regressed - not in the strictly expo-
nential fashion that had previously been proposed (Skipper and
Schabel, 1982) but in a Gompertzian manner. The essential feature
ofGompertzian kinetics is that the growth fraction ofthe tumour is
not constant, as would be predicted by the exponential model, but
rather varies with the size of the tumour. As tumours grow larger,
their growth rate decreases. They further hypothesized that the rate
of regression of a cancer was related to the dose of chemotherapy
administered and to the growth rate of the unperturbed tumour at
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that phase ofits growth curve. Thus, small tumours should be rela-
tively more sensitive to chemotherapy than large ones. Para-
doxically, the very high growth rate of very small, subclinical
tumours makes their eradication difficult to achieve. Thus,
according to Norton and Simon (1986), a phase of 'late intensifica-
tion' oftherapy would be necessary to eradicate a tumour that had
been cytoreduced by prior conventional chemotherapy. In the
1970s and 1980s, many groups had studied this approach (using
doses substantially less intensive than those achieved with auto-
grafting) in patients with different cancers. While some of these
trials were positive, the benefit was generally modest (Perloffet al,
1996). The fact that this strategy did not have a greater curative
impact might indicate that the level oflate intensification achieved
in these studies was insufficiently high to have a meaningful
impact on drug resistance. Thus, autografting, which facilitated
substantial dose-escalation, and the Norton-Simon model seemed
to be made for one other. A further theoretical advantage of the
,standard-dose induction' - 'high-dose consolidation' approach
was that it identified patients with resistant disease who were
known not to benefit substantially from high-dose therapy.
This strategy became the dominant model, and it produced rela-
tively consistent results. Overall and complete response rates were
approximately 80-90% and 50-70% respectively. Most of these
remissions still ended in relapse, however, and the results were not
convincingly superior to those that had been reported for high-dose
chemotherapy without prior induction. Nevertheless, the occurrence
ofdurable remissions in 10-20% ofpatients suggestedthepossibility
that this might be a curative treatment for a minority ofpatients with
metastatic disease (Kennedy et al, 1991; Antman et al, 1992; Crown
et al, 1995) There was, ofcourse, a substantial potential for selection
bias in these single-arm studies, and there was general acceptance of
the need for prospective randomized trials (Henderson, 1990).
However, even if these results were to be confirmed, high-dose
therapy would remain a poor treatment for metastatic disease, with
only a small minority ofpatients achieving durable remissions. With
the decline in treatment-related mortality that occurred following the
introduction of peripheral blood progenitors, (Gianni et al, 1989;
Brugger et al, 1993; Peters et al, 1993a) relapse from complete
remission had in fact emerged as the leading cause offailure.
An interpretation of these results based on the Goldie-Coldman
model would suggest that these relapses were inevitably due to the
persistence, or emergence, of diverse clones of cancer cells with
varying drug resistance mechanisms (Goldie and Coldman, 1979).
In an attempt to overcome this problem, Gianni et al (1992)
devised innovative regimens which sequentially delivered high
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doses of different single agents that were putatively susceptible
to different drug-resistance mechanisms (Patrone et al, 1995).
Both the 'induction-consolidation' and the 'high-dose sequential
models' are, however, based on the premise that populations of
cells that are sensitive to a treatment can be efficiently eradicated
by a single application of that treatment - a hypothesis which is
not entirely consistent with classical chemotherapy theory and
practice (Crown and Norton, 1995). The cure ofHodgkin's disease
(DeVita et al, 1970) and testis cancer (Einhom et al, 1977) resulted
from the identification of highly active regimens and the applica-
tion ofa sufficient number ofcycles ofthose regimens to eradicate
the cancer. As the high-dose programmes used with stem-cell
support appear to be the most active regimens that are currently
available for the treatment ofmetastatic breast cancer, would it not
be logical to treat patients with multiple cycles of these highly
active regimens rather than prefacing their use with treatments
that, in the context ofcure, are highly ineffective?
This approach might in fact be more consistent with the
Norton-Simon model, the ultimate logic of which is that all treat-
ment courses should be given in high dose. Furthermore, the
observation that Gompertzian kinetics predicted rapid regrowth of
small volume residual tumours argues for abbreviated treatment
intervals. In the 1970s (when this hypothesis was first advanced),
haematopoietic support technology was rudimentary, and a single
cycle of high-dose therapy was as much as most, but not all,
(Dunphy and Spitzer, 1992) investigators attempted. Thus induc-
tion - consolidation was the most feasible adaptation ofthe model
at that point in time. The introduction ofperipheral blood progeni-
tors subsequently facilitated the investigation ofmulti-cycle high-
dose therapy at either standard or accelerated treatment intervals.
This strategy is now under investigation (Crown et al, 1992, 1993,
1994; Ayash et al, 1994; Fennelly et al, 1995, Vahdat et al, 1995;
Rodenhuis et al, 1996). It is against this historical and theoretical
backdrop that we should consider the results of the first two
randomized studies of high-dose chemotherapy in metastatic
breast cancer.
Bezwoda et al (1995) randomly assigned patients with chemo-
therapy-naive metastatic disease to receive either conventionally-
dosed mitoxantrone, vincristine and cyclophosphamide or
high-doses of cyclophosphamide, etoposide and mitoxantrone
without induction therapy. The high-dose treatment produced
significantly superior response and survival. The study was rela-
tively small, and a disproportionate number of patients on the
high-dose arm received tamoxifen post chemotherapy. In addition,
patients on the low-dose arm had rather poor survival. It is,
however, interesting to note that many ofthe patients on the high-
dose arm were not hospitalized for complications of cytopenia, a
finding which suggests that this high-dose regimen was less inten-
sive that those that had been used in other studies.
The second study (Peters et al, 1996) was a test of the classic
induction - high-dose consolidation model. Patients with
metastatic breast cancer who had achieved a complete response to
conventional chemotherapy were randomized to undergo high-
dose therapy as immediate consolidation or to receive no further
treatment until they relapsed; 'salvage' high-dose chemotherapy
was then applied. The cohort who underwent consolidation had a
highly significantly prolonged disease-free survival compared
with those who were transplanted at relapse, supporting the
concept of 'late-intensification'. Paradoxically, the latter group of
patients had superior overall survival. While this apparently
confusing observation requires explanation and confirmation,
high-dose chemotherapy was, again, associated with 5-year
survival in a proportion of patients, including non-randomized
patients who were transplanted in partial response. A further
implication ofthese results is that a reconsideration ofthis therapy
in relapsed metastatic disease may be required.
It may be that these two trials taken collectively show us that
high-dose therapy is indeed more active than low-dose therapy, but
that the induction - consolidation model might not represent its
most efficient use. While these studies partly establish the credi-
bility of high-dose therapy, conventionally dosed chemotherapy
has also improved in recent years, and it is essential that the
conventional arms of future confirmatory trials should also be
optimized. In one such initiative, the European Breast Cancer
Dose-Intensity Study (EBDIS), patients receive docetaxel and
anthracycline followed by either cyclophosphamide methotrexate
5-fluorouracil (CMF) or two autograft-supported high-dose
cycles. In future studies, investigators will likely address the rela-
tive merits of the different high-use strategies and the potential
impact of graft engineering (Shpall et al, 1994; Brugger et al,
1995). The impact ofhigh-dose chemotherapy may also be greater
in the setting of high-risk stage II-III disease in which the tumour
burden is much smaller than it is in patients with clinically overt
metastases. Promising results have been reported from single-arm
studies (Gianni et al, 1992; Peters et al, 1993b), and this approach
is now the subject oflarge international randomized trials.
The last year has been an exciting one for students ofhigh-dose
therapy. We may bejustified in believing that the first randomized
trials have brought us to the 'end of the beginning'. Hopefully,
current studies may herald the 'beginning ofthe end'.
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